Peptide · Fact sheet

Teduglutide

Also known as Gattex · Revestive · GLP-2 analog

Teduglutide is FDA approved as Gattex for adults and children 1 year and older with short bowel syndrome who depend on parenteral support. It is not approved for routine gut health, inflammatory bowel disease, food intolerance, or wellness.

FDA approved for specific usesStrong human evidence for approved uses

Gut & immune health Specific conditions

What is Teduglutide?

Teduglutide is a long-acting analog of glucagon-like peptide 2, a hormone that supports intestinal growth, blood flow, and absorption.

Its clinical endpoint is reduced need for parenteral nutrition or fluids in short bowel syndrome, not a vague measure of gut repair.

Benefits people look for

It is a strong example of a peptide improving organ function through tissue adaptation rather than weight or hormone-release effects.

Its growth-promoting mechanism also explains important polyp, neoplasia, obstruction, and fluid-related safety concerns.

What the evidence supports

Controlled trials found that more participants reduced parenteral-support volume than with placebo.
Some long-term studies report further support reduction, but response varies and the therapy does not restore normal anatomy.

All research areas

Short bowel syndrome
Intestinal absorption
Parenteral-support reduction
Pediatric intestinal failure

Long-term intestinal autonomy and outcomes in selected intestinal-failure populations

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.

We do not fill this gap with unsourced testimonials or estimated success rates.

Side effects & risks

The label warns about accelerated neoplastic growth and requires attention to gastrointestinal polyps and malignancy risk.
Intestinal obstruction, biliary and pancreatic disease, and fluid overload are important labeled risks.
Increased absorption can change exposure to other oral medicines.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Strong human evidence for approved uses

Randomized trials support reduced parenteral-support requirements in the labeled population. That evidence does not transfer to general digestive symptoms or unapproved gut-healing claims.

Selected research to read

Randomized teduglutide short bowel syndrome trial ↗

Controlled evidence for reduced parenteral nutrition and fluid requirements.

Phase 3 and extension study in Japan ↗

Small longer-term study illustrating response durability and population limits.

FDA approval & research status

Gattex is FDA approved for adults and pediatric patients 1 year of age and older with short bowel syndrome who are dependent on parenteral support.

Approved uses covered here

Treatment of short bowel syndrome with dependence on parenteral support in the age groups specified by the Gattex label

FDA approved for short bowel syndrome

Teduglutide is approved under the Gattex label for short bowel syndrome with parenteral-support dependence in specified age groups.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

Very long-term malignancy and polyp outcomes
Which patients can achieve durable independence from parenteral support
How pediatric outcomes evolve across growth and development
Whether benefits persist after treatment ends

The takeaway

Teduglutide has a meaningful, narrow intestinal-failure role. Its evidence cannot be repackaged as proof of a general gut-repair peptide.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

1
fdaFDA prescribing information: Gattex
Current indication, warnings, adverse reactions, and clinical studies.
2
pubmedRandomized teduglutide short bowel syndrome trial
Controlled evidence for reduced parenteral nutrition and fluid requirements.
3
pubmedPhase 3 and extension study in Japan
Small longer-term study illustrating response durability and population limits.

How we assess sources · Suggest a correction